World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
83
Citations
28751
World Ranking
15496
National Ranking
7811

Filip Janku publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Filip Janku sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 868 publications — 90th percentile

90% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Filip Janku D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Filip Janku sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 83 D-Index — 24th percentile

24% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Filip Janku is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with significant contributions in Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Cancer Research, and Genetics.

Their work covers a broad spectrum of topics, including:

  • Cancer Genomics and Diagnostics
  • Lung Cancer Treatments and Mutations
  • Cancer Immunotherapy and Biomarkers
  • Cancer Research and Treatments
  • PI3K/AKT/mTOR signaling in cancer
  • Colorectal Cancer Treatments and Studies
  • Cancer-related Molecular Pathways

Frequent coauthors in their research include Funda Meric-Bernstam, Sarina A. Piha-Paul, David S. Hong, Apostolia M. Tsimberidou, and Aung Naing, reflecting collaboration across multiple studies.

Filip Janku has published extensively, with numerous articles appearing in key scientific journals. Predominant venues for their work are:

  • Journal of Clinical Oncology
  • Cancer Research
  • Annals of Oncology
  • Regular and Young Investigator Award Abstracts
  • Clinical Cancer Research

Selected recent papers authored or coauthored by Filip Janku include:

  • Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era, 2020, Blood
  • Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma, 2020, Journal of Clinical Oncology
  • Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial, 2021, Clinical Cancer Research
  • Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma, 2020, Journal of Clinical Oncology
  • Intratumoral Injection of Clostridium novyi-NT Spores in Patients with Treatment-refractory Advanced Solid Tumors, 2020, Clinical Cancer Research

Best Publications

  • Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages.

    Jean-François Emile;Oussama Abla;Sylvie Fraitag;Annacarin Horne

  • Targeting the PI3K pathway in cancer: are we making headway?

    Filip Janku;Timothy A. Yap;Funda Meric-Bernstam

  • Autophagy as a target for anticancer therapy

    Filip Janku;David J. McConkey;David S. Hong;Razelle Kurzrock

  • Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.

    Scott Kopetz;Jayesh Desai;Emily Chan;Joel Randolph Hecht

  • Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease

    Eli L. Diamond;Lorenzo Dagna;David M. Hyman;Giulio Cavalli

  • Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative

    Apostolia M. Tsimberidou;Nancy G. Iskander;David S. Hong;Jennifer J. Wheler

  • PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations

    Filip Janku;Jennifer J. Wheler;Shannon N. Westin;Stacy L. Moulder

  • Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms

    Eli L. Diamond;Benjamin H. Durham;Julien Haroche;Zhan Yao

  • Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications

    Chaitanya R. Churi;Rachna Shroff;Ying Wang;Asif Rashid

  • Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials

    Funda Meric-Bernstam;Lauren Brusco;Kenna Shaw;Chacha Horombe

  • PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors

    Filip Janku;Apostolia Maria Tsimberidou;Ignacio Garrido-Laguna;Xuemei Wang

  • A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors

    Philippe L. Bedard;Josep Tabernero;Filip Janku;Zev A. Wainberg

  • Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses

    Nicholas J. Roberts;Linping Zhang;Filip Janku;Amanda Collins

  • Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study

    Dejan Juric;Jordi Rodon;Josep Tabernero;Filip Janku

  • First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study

    Ryan J. Sullivan;Jeffrey R. Infante;Filip Janku;Deborah Jean Lee Wong

  • Targeted therapy in non-small-cell lung cancer—is it becoming a reality?

    Filip Janku;David J. Stewart;Razelle Kurzrock

  • PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials

    Filip Janku;Jennifer J. Wheler;Aung Naing;Gerald S. Falchook

  • Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era

    Gaurav Goyal;Mark L. Heaney;Matthew Collin;Matthew Collin;Fleur Cohen-Aubart

  • Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.

    Filip Janku;David S. Hong;Siqing Fu;Sarina A. Piha-Paul

  • Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment

    M. P. Morelli;M. J. Overman;A. Dasari;S. M.A. Kazmi

Frequent Co-Authors

David S. Hong
David S. Hong The University of Texas MD Anderson Cancer Center
Sarina Anne Piha-Paul
Sarina Anne Piha-Paul The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam
Funda Meric-Bernstam The University of Texas MD Anderson Cancer Center
Apostolia Maria Tsimberidou
Apostolia Maria Tsimberidou The University of Texas MD Anderson Cancer Center
Razelle Kurzrock
Razelle Kurzrock Medical College of Wisconsin
Kenneth R. Hess
Kenneth R. Hess The University of Texas MD Anderson Cancer Center
Rajyalakshmi Luthra
Rajyalakshmi Luthra The University of Texas MD Anderson Cancer Center
Scott Kopetz
Scott Kopetz The University of Texas MD Anderson Cancer Center
Michael J. Overman
Michael J. Overman The University of Texas MD Anderson Cancer Center
Milind Javle
Milind Javle The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in careers beyond traditional medical practice, a variety of related online degrees offer alternative pathways within healthcare. For example, earning a bachelors in health administration can open doors to management and leadership roles in hospitals, clinics, and long-term care facilities.

Advancing with a graduate degree, students often consider a Master of Healthcare Administration (MHA). Factors such as mha degree cost play a critical role in decision-making, with affordable online options making this career step more accessible.

Nurses aiming for leadership or advanced clinical positions may pursue terminal degrees. Researching the least expensive dnp programs online can help registered nurses become nurse practitioners or nurse executives at a lower financial burden.

Pharmacy professionals are also turning to online doctorates. Those who want to become pharmacists can explore online pharmd programs that provide flexibility and affordability.

Ultimately, whether you are interested in administration, nursing, or pharmacy, online degrees can offer diverse, cost-effective paths toward a rewarding healthcare career.

Best Scientists Citing Filip Janku

Trending Scientists

Recently Published Articles